ElizabethKeatingO'DonnellMD

PubMed

• 30 citations
  Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
  Kenneth C. Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson
  Clinical Cancer Research. 2021-07-28
• 42 citations
  Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
  Guangwu Guo, Noopur Raje, Charles Seifer, Jake A. Kloeber, Randi Isenhart
  Leukemia. 2018-03-27
• 688 citations
  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
  Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha
  Lancet. 2021-07-24

Abstracts/Posters

• Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
  Elizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
  Elizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Elizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019